within Pharmacolibrary.Drugs.ATC.M;

model M05BX03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 2000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.023,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006666666666666667,
    Tlag           = 10.200000000000001,            
    Vdp             = 0.079,
    k12             = 2.46,
    k21             = 2.46
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M05BX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Strontium ranelate is a medication formerly approved for the treatment of osteoporosis in postmenopausal women and men at increased risk of fractures. Due to concerns about cardiovascular risk, its use is now restricted or withdrawn in many countries. It works by simultaneously promoting bone formation and reducing bone resorption.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult volunteers after oral administration at therapeutic dose.</p><h4>References</h4><ol><li><p>Zhang, D, et al., &amp; Liu, H (2019). Pharmacokinetics and bioequivalence of two strontium ranelate formulations after single oral administration in healthy Chinese subjects. <i>Xenobiotica; the fate of foreign compounds in biological systems</i> 49(4) 457–462. DOI:<a href=&quot;https://doi.org/10.1080/00498254.2018.1465210&quot;>10.1080/00498254.2018.1465210</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29676197/&quot;>https://pubmed.ncbi.nlm.nih.gov/29676197</a></p></li><li><p>Reginster, JY (2002). Strontium ranelate in osteoporosis. <i>Current pharmaceutical design</i> 8(21) 1907–1916. DOI:<a href=&quot;https://doi.org/10.2174/1381612023393639&quot;>10.2174/1381612023393639</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12171530/&quot;>https://pubmed.ncbi.nlm.nih.gov/12171530</a></p></li><li><p>Reginster, JY, et al., &amp; Jupsin, I (2003). Strontium ranelate: a new paradigm in the treatment of osteoporosis. <i>Drugs of today (Barcelona, Spain : 1998)</i> 39(2) 89–101. DOI:<a href=&quot;https://doi.org/10.1358/dot.2003.39.2.799416&quot;>10.1358/dot.2003.39.2.799416</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12698204/&quot;>https://pubmed.ncbi.nlm.nih.gov/12698204</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M05BX03;
